Novo Nordisk (NYSE: NVO)
Novo Nordisk Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Novo Nordisk Company Info
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
News & Analysis
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run
Medicare just revised its guidelines to include coverage of Wegovy for patients with cardiovascular complications.
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
These stocks are trading at sky-high valuations which could make them vulnerable to sell-offs.
Where Will Novo Nordisk Be in 10 Years?
Will Novo Nordisk top $1 trillion in market value?
Is Novo Nordisk Stock a Millionaire Maker?
Novo Nordisk's stock may look expensive today, but that may not be the case in even a year or two.
These Are Billionaires’ Favorite Healthcare Stocks
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today
Back then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days.
Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy.
This company is serious about maintaining its leadership.
How Many Small-Cap Stocks Are There?
The number changes quickly.
Valuation
Earnings Transcripts
Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript
NVO earnings call for the period ending March 31, 2024.
Novo Nordisk (NVO) Q4 2023 Earnings Call Transcript
NVO earnings call for the period ending December 31, 2023.
Novo Nordisk (NVO) Q3 2023 Earnings Call Transcript
NVO earnings call for the period ending September 30, 2023.
Novo Nordisk (NVO) Q2 2023 Earnings Call Transcript
NVO earnings call for the period ending June 30, 2023.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.